trial · primary record
Cilta-cel
Multiple Myeloma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 43 |
| Primary completion | 2030-09-30 |
| Primary endpoint | Rate of Response with Curative Potential |
| Registry ID | NCT06577025 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:58.714Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06577025
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cilta-cel · compound